Bacteriophage combinations significantly reduce Clostridium difficile growth in vitro and proliferation in vivo

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 2, 2016, Pages 968-981

  Nale, Janet Y ^a   Spencer, Janice ^b   Hargreaves, Katherine R ^a,b   Trzepiński, Przemysław ^a   Douce, Gillian R ^b   Clokie, Martha R J ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN PHOSPHATE; MITOMYCIN; NORFLOXACIN; BACTERIAL TOXIN; CLOSTRIDIUM DIFFICILE LETHAL TOXIN B;

ANIMAL EXPERIMENT; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIAL LOAD; BACTERIAL STRAIN; BACTERIUM CULTURE; CELL PROLIFERATION; CLOSTRIDIUM DIFFICILE INFECTION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; EPIDEMIC; IN VITRO STUDY; IN VIVO STUDY; LIMIT OF DETECTION; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PHYLOGENY; PRIORITY JOURNAL; PROPHAGE; SINGLE DRUG DOSE; TRANSMISSION ELECTRON MICROSCOPY; ANIMAL; BACTERIAL SPORE; BACTERIOPHAGE; CLASSIFICATION; CLOSTRIDIUM INFECTION; DISEASE MODEL; FEMALE; GENETICS; GROWTH, DEVELOPMENT AND AGING; HOST RANGE; MESOCRICETUS; METABOLISM; PATHOGENICITY; PHYSIOLOGY; RIBOTYPING; VIROLOGY;

ANIMALS; BACTERIAL TOXINS; BACTERIOPHAGES; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DISEASE MODELS, ANIMAL; FEMALE; HOST SPECIFICITY; MESOCRICETUS; PHYLOGENY; RIBOTYPING; SPORES, BACTERIAL;

EID: 84957922991     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01774-15     Document Type: Article

References (76)

1. McFarland LV. 1998. Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. Dig Dis 16:292-307. http://dx.doi.org/10.1159/000016879.
2. Wilcox MH, Shetty N, Fawley WN, Shemko M, Coen P, Birtles A, Cairns M, Curran MD, Dodgson KJ, Green SM, Hardy KJ, Hawkey PM, Magee JG, Sails AD, Wren MWD. 2012. Changing epidemiology of Clostridium difficile infection following the introduction of a national ribotyping-based surveillance scheme in England. Clin Infect Dis 55:1056-1063. http://dx.doi.org/10.1093/cid/cis614.
3. Bauer MP, Notermans DW, van Benthem BHB, Brazier JS, Wilcox MH, Rupnik M, Monnet DL, van Dissel JT. 2011. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 377:63-73. http://dx.doi.org/10.1016/S0140-6736(10)61266-4.
4. Wilcox MH, Fawley WN. 2000. Hospital disinfectants and spore formation by Clostridium difficile. Lancet 356:1324. http://dx.doi.org/10.1016/S0140-6736(00)02819-1.
5. Wiegand PN, Nathwani D, Wilcox MH, Stephens J, Shelbaya A, Haider S. 2012. Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. J Hosp Infect 81:1-14. http://dx.doi.org/10.1016/j.jhin.2012.02.004.
6. Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, Farley MM, Holzbauer SM, Meek JI, Phipps EC, Wilson LE, Winston LG, Cohen JA, Limbago BM, Fridkin SK, Gerding DN, McDonald LC. 2015. Burden of Clostridium difficile infection in the United States. N Engl J Med 372:825-834. http://dx.doi.org/10.1056/NEJMoa1408913.
7. Crawford T, Huesgen E, Danziger L. 2012. Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection. Am J Health Syst Pharm 69:933-943. http://dx.doi.org/10.2146/ajhp110371.
8. Aslam S, Hamill RJ, Musher DM. 2005. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis 5:549-557. http://dx.doi.org/10.1016/S1473-3099(05)70215-2.
9. Pepin J. 2008. Vancomycin for the treatment of Clostridium difficile infection: for whom is this expensive bullet really magic? Clin Infect Dis 46:1493-1498. http://dx.doi.org/10.1086/587656.
10. Bartsch SM, Umscheid CA, Fishman N, Lee BY. 2013. Is fidaxomicin worth the cost? An economic analysis. Clin Infect Dis 57:555-561. http://dx.doi.org/10.1093/cid/cit346.
11. Stranges PM, Hutton DW, Collins CD. 2013. Cost-effectiveness analysis evaluating fidaxomicin versus oral vancomycin for the treatment of Clostridium difficile infection in the United States. Value Health 16:297-304. http://dx.doi.org/10.1016/j.jval.2012.11.004.
12. Zucca M, Scutera S, Savoia D. 2013. Novel avenues for Clostridium difficile infection drug discovery. Expert Opin Drug Discov 8:459-477. http://dx.doi.org/10.1517/17460441.2013.770466.
13. Freeman J, Baines SD, Jabes D, Wilcox MH. 2005. Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection. J Antimicrob Chemother 56:717-725. http://dx.doi.org/10.1093/jac/dki321.
14. Hargreaves KR, Clokie MRJ. 2014. Clostridium difficile phages: still difficult? Front Microbiol 5:184. http://dx.doi.org/10.3389/fmicb.2014.00184.
15. Sangster W, Hegarty JP, Stewart DB. 2014. Phage therapy for Clostridium difficile infection: an alternative to antibiotics? Semin Colon Rectal Surg 25:167-170. http://dx.doi.org/10.1053/j.scrs.2014.05.014.
16. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. 2011. Phage treatment of human infections. Bacteriophage 1:66-85. http://dx.doi.org/10.4161/bact.1.2.15845.
17. Loc-Carrillo C, Abedon ST. 2011. Pros and cons of phage therapy. Bacteriophage 1:111-114. http://dx.doi.org/10.4161/bact.1.2.14590.
18. Nilsson AS. 2014. Phage therapy - constraints and possibilities. Uppsala J Med Sci 119:192-198. http://dx.doi.org/10.3109/03009734.2014.902878.
19. Parasion S, Kwiatek M, Gryko R, Mizak L, Malm A. 2014. Bacteriophages as an alternative strategy for fighting biofilm development. Pol J Microbiol 63:137-145.
20. Payne RJH, Jansen VAA. 2000. Phage therapy: the peculiar kinetics of self-replicating pharmaceuticals. Clin Pharmacol Ther 68:225-230. http://dx.doi.org/10.1067/mcp.2000.109520.
21. Fu W, Forster T, Mayer O, Curtin JJ, Lehman SM, Donlan RM. 2010. Bacteriophage cocktail for the prevention of biofilm formation by Pseudomonas aeruginosa on catheters in an in vitro model system. Antimicrob Agents Chemother 54:397-404. http://dx.doi.org/10.1128/AAC.00669-09.
22. Azeredo J, Sutherland IW. 2008. The use of phages for the removal of infectious biofilms. Curr Pharm Biotechnol 9:261-266. http://dx.doi.org/10.2174/138920108785161604.
23. Brüssow H. 2012. What is needed for phage therapy to become a reality in Western medicine? Virology 434:138-142. http://dx.doi.org/10.1016/j.virol.2012.09.015.
24. Slopek S, Weber-Dabrowska B, Dabrowski M, Kucharewicz-Krukowska A. 1987. Results of bacteriophage treatment of suppurative bacterial infections in the years 1981-1986. Arch Immunol Ther Exp (Warsz) 35:569-583.
25. Chan BK, Abedon ST, Loc-Carrillo C. 2013. Phage cocktails and the future of phage therapy. Future Microbiol 8:769-783. http://dx.doi.org/10.2217/fmb.13.47.
26. Kutter EM, Kuhl SJ, Abedon ST. 2015. Re-establishing a place for phage therapy in Western medicine. Future Microbiol 10:685-688. http://dx.doi.org/10.2217/fmb.15.28.
27. EBI Food Safety. 2007. FDA and USDA extend GRAS approval for LISTEX for all food products. EBI Food Safety, Wageningen, Netherlands.
28. Hagens S, Loessner MJ. 2010. Bacteriophage for biocontrol of foodborne pathogens: calculations and considerations. Curr Pharm Biotechnol 1:58-68.
29. Ramesh V, Fralick JA, Rolfe RD. 1999. Prevention of Clostridium difficile-induced ileocecitis with bacteriophage. Anaerobe 5:69-78. http://dx.doi.org/10.1006/anae.1999.0192.
30. Govind R, Fralick JA, Rolfe RD. 2011. In vivo lysogenization of a Clostridium difficile bacteriophage ΦCD119. Anaerobe 17:125-129. http://dx.doi.org/10.1016/j.anaerobe.2011.05.012.
31. Goh S, Hussain H, Chang BJ, Emmett W, Riley TV, Mullany P. 2013. Phage φC2 mediates transduction of Tn6215, encoding erythromycin resistance, between Clostridium difficile strains. mBio 4:e00840-13. http://dx.doi.org/10.1128/mBio.00840-13.
32. Govind R, Vediyappan G, Rolfe RD, Dupuy B, Fralick JA. 2009. Bacteriophage-mediated toxin gene regulation in Clostridium difficile. J Virol 83:12037-12045. http://dx.doi.org/10.1128/JVI.01256-09.
33. Goh S, Chang BJ, Riley TV. 2005. Effect of phage infection on toxin production by Clostridium difficile. J Med Microbiol 54:129-135. http://dx.doi.org/10.1099/jmm.0.45821-0.
34. Sekulovic O, Meessen-Pinard M, Fortier LC. 2011. Prophage-stimulated toxin production in Clostridium difficile NAP1/027 lysogens. J Bacteriol 193:2726-2734. http://dx.doi.org/10.1128/JB.00787-10.
35. Meader E, Mayer MJ, Gasson MJ, Steverding D, Carding SR, Narbad A. 2010. Bacteriophage treatment significantly reduces viable Clostridium difficile and prevents toxin production in an in vitro model system. Anaerobe 16:549-554. http://dx.doi.org/10.1016/j.anaerobe.2010.08.006.
36. Dalmasso M, Hill C, Ross RP. 2014. Exploiting gut bacteriophages for human health. Trends Microbiol 22:399-405. http://dx.doi.org/10.1016/j.tim.2014.02.010.
37. Sangster W, Hegarty JP, Stewart DB. 2015. Phage tail-like particles kill Clostridium difficile and represent an alternative to conventional antibiotics. Surgery 157:96-103. http://dx.doi.org/10.1016/j.surg.2014.06.015.
38. Rinttilä T, Kassinen A, Malinen E, Krogius L, Palva A. 2004. Development of an extensive set of 16S rDNA-targeted primers for quantification of pathogenic and indigenous bacteria in faecal samples by real-time PCR. J Appl Microbiol 97:1166-1177. http://dx.doi.org/10.1111/j.1365-2672.2004.02409.x.
39. Indra A, Huhulescu S, Schneeweis M, Hasenberger P, Kernbichler S, Fiedler A, Wewalka G, Allerberger F, Kuijper EJ. 2008. Characterization of Clostridium difficile isolates using capillary gel electrophoresis-based PCR ribotyping. J Med Microbiol 57:1377-1382. http://dx.doi.org/10.1099/jmm.0.47714-0.
40. Hargreaves KR, Colvin HV, Patel KV, Clokie J, Clokie MRJ. 2013. Genetically diverse Clostridium difficile strains harbouring abundant prophages in an estuarine environment. Appl Environ Microbiol 79:6236-6243. http://dx.doi.org/10.1128/AEM.01849-13.
41. Hargreaves KR, Kropinski AM, Clokie MRJ. 2014. What does the talking?: quorum sensing signalling genes discovered in a bacteriophage genome. PLoS One 9:e85131. http://dx.doi.org/10.1371/journal.pone.0085131.
42. Mahony DE, Bell PD, Easterbrook KB. 1985. Two bacteriophages of Clostridium difficile. J Clin Microbiol 21:251-254.
43. Nale JY, Shan J, Hickenbotham PT, Fawley WN, Wilcox MH, Clokie MRJ. 2012. Diverse temperate bacteriophage carriage in Clostridium difficile 027 strains. PLoS One 7:e37263. http://dx.doi.org/10.1371/journal.pone.0037263.
44. Aziz RK, Bartels D, Best AA, DeJongh M, Disz T, Edwards RA, Formsma K, Gerdes S, Glass EM, Kubal M, Meyer F, Olsen GJ, Olson R, Osterman AL, Overbeek RA, McNeil LK, Paarmann D, Paczian T, Parrello B, Pusch GD, Reich C, Stevens R, Vassieva O, Vonstein V, Wilke A, Zagnitko O. 2008. The RAST server: Rapid Annotations Using Subsystems Technology. BMC Genomics 9:75-75. http://dx.doi.org/10.1186/1471-2164-9-75.
45. Kearse M, Moir R, Wilson A, Stones-Havas S, Cheung M, Sturrock S, Buxton S, Cooper A, Markowitz S, Duran C, Thierer T, Ashton B, Meintjes P, Drummond A. 2012. Geneious basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data. Bioinformatics 28:1647-1649. http://dx.doi.org/10.1093/bioinformatics/bts199.
46. Kim GH, Kim J, Pai H, Kang JO. 2014. Comparison of supplemented brucella agar and modified Clostridium difficile agar for antimicrobial susceptibility testing of Clostridium difficile. Ann Lab Med 34:439-445. http://dx.doi.org/10.3343/alm.2014.34.6.439.
47. Best EL, Freeman J, Wilcox MH. 2012. Models for the study of Clostridium difficile infection. Gut Microbes 3:145-167. http://dx.doi.org/10.4161/gmic.19526.
48. Hargreaves KR, Flores CO, Lawley TD, Clokie MRJ. 2014. Abundant and diverse clustered regularly interspaced short palindromic repeat spacers in Clostridium difficile strains and prophages target multiple phage types within this pathogen. mBio 5:e01045-13. http://dx.doi.org/10.1128/mBio.01045-13.
49. Hargreaves KR, Otieno JR, Thanki A, Blades MJ, Millard AD, Browne HP, Lawley TD, Clokie MRJ. 2015. As clear as mud? Determining the diversity and prevalence of prophages in the draft genomes of estuarine isolates of Clostridium difficile. Genome Biol Evol 7:1842-1855. http://dx.doi.org/10.1093/gbe/evv094.
50. Bull AL, Worth LJ, Richards MJ. 2012. Implementation of standardised surveillance for Clostridium difficile infections in Australia: initial report from the Victorian Healthcare Associated Infection Surveillance System. Intern Med J 42:715-718. http://dx.doi.org/10.1111/j.1445-5994.2012.02804.x.
51. Freeman J, Bauer MP, Baines SD, Corver J, Fawley WN, Goorhuis B, Kuijper EJ, Wilcox MH. 2010. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 23:529-549. http://dx.doi.org/10.1128/CMR.00082-09.
52. Cheknis AK, Sambol SP, Davidson DM, Nagaro KJ, Mancini MC, Aida Hidalgo-Arroyo G, Brazier JS, Johnson S, Gerding DN. 2009. Distribution of Clostridium difficile strains from a North American, European and Australian trial of treatment for C. difficile infections: 2005-2007. Anaerobe 15:230-233. http://dx.doi.org/10.1016/j.anaerobe.2009.09.001.
53. Emerging Infections Program. 2011. Investigating Clostridium difficile infections across the U.S. Emerging Infections Program, Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/hai/eip/pdf/Cdiff-factsheet.pdf.
54. Goorhuis A, Bakker D, Corver J, Debast SB, Harmanus C, Notermans DW, Bergwerff AA, Dekker FW, Kuijper EJ. 2008. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 47:1162-1170. http://dx.doi.org/10.1086/592257.
55. Public Health England. 2013. Clostridium difficile Ribotyping Network (CDRN) for England and Northern Ireland 2011-13 report. Public Health England, London, United Kingdom. https://www.gov.uk/government/uploads/system/uploads/attachment-data/file/329156/C-difficile-ribotyping-network-CDRN-report.pdf.
56. van den Berg RJ, Ameen HAA, Furusawa T, Claas ECJ, van der Vorm ER, Kuijper EJ. 2005. Coexistence of multiple PCR-ribotype strains of Clostridium difficile in faecal samples limits epidemiological studies. J Med Microbiol 54:173-179. http://dx.doi.org/10.1099/jmm.0.45825-0.
57. Marsh JW, O'Leary MM, Shutt KA, Pasculle AW, Johnson S, Gerding DN, Muto CA, Harrison LH. 2006. Multilocus variable-number tandem-repeat analysis for investigation of Clostridium difficile transmission in hospitals. J Clin Microbiol 44:2558-2566. http://dx.doi.org/10.1128/JCM.02364-05.
58. Buckley AM, Spencer J, Maclellan LM, Candlish D, Irvine JJ, Douce GR. 2013. Susceptibility of hamsters to Clostridium difficile isolates of differing toxinotype. PLoS One 8:e64121. http://dx.doi.org/10.1371/journal.pone.0064121.
59. Meader E, Mayer MJ, Steverding D, Carding SR, Narbad A. 2013. Evaluation of bacteriophage therapy to control Clostridium difficile and toxin production in an in vitro human colon model system. Anaerobe 22:25-30. http://dx.doi.org/10.1016/j.anaerobe.2013.05.001.
60. Goh S, Riley TV, Chang BJ. 2005. Isolation and characterization of temperate bacteriophages of Clostridium difficile. Appl Environ Microbiol 71:1079-1083. http://dx.doi.org/10.1128/AEM.71.2.1079-1083.2005.
61. Horgan M, O'Sullivan O, Coffey A, Fitzgerald GF, van Sinderen D, McAuliffe O, Ross RP. 2010. Genome analysis of the Clostridium difficile phage phiCD6356, a temperate phage of the Siphoviridae family. Gene 462:34-43. http://dx.doi.org/10.1016/j.gene.2010.04.010.
62. Meessen-Pinard M, Sekulovic O, Fortier LC. 2012. Evidence of in vivo prophage induction during Clostridium difficile infection. Appl Environ Microbiol 78:7662-7670. http://dx.doi.org/10.1128/AEM.02275-12.
63. Public Health England. 2013. Quarterly epidemiological commentary: mandatory MRSA, MSSA and E. coli bacteraemia, and C. difficile infection data (up to January-March 2013). Public Health England, London, United Kingdom. http://www.hpa.org.uk/webc/HPAwebFile/HPAweb-C/1284473407318.
64. Vanek J, Hill K, Collins J, Berrington A, Perry J, Inns T, Gorton R, Magee J, Sails A, Mullan A, Gould FK. 2012. Epidemiological survey of Clostridium difficile ribotypes in the north east of England during an 18-month period. J Hosp Infect 81:209-212. http://dx.doi.org/10.1016/j.jhin.2012.04.017.
65. Janezic S, Zidaric V, Pardon B, Indra A, Kokotovic B, Blanco J, Seyboldt C, Diaz C, Poxton I, Perreten V, Drigo I, Jiraskova A, Ocepek M, Weese J, Songer J, Wilcox M, Rupnik M. 2014. International Clostridium difficile animal strain collection and large diversity of animal associated strains. BMC Microbiol 14:173. http://dx.doi.org/10.1186/1471-2180-14-173.
66. Fawley WN, Freeman J, Smith C, Harmanus C, van den Berg RJ, Kuijper EJ, Wilcox MH. 2008. Use of highly discriminatory fingerprinting to analyze clusters of Clostridium difficile infection cases due to epidemic ribotype 027 strains. J Clin Microbiol 46:954-960. http://dx.doi.org/10.1128/JCM.01764-07.
67. Mayer MJ, Narbad A, Gasson MJ. 2008. Molecular characterization of a Clostridium difficile bacteriophage and its cloned biologically active endolysin. J Bacteriol 190:6734-6740. http://dx.doi.org/10.1128/JB.00686-08.
68. Hyman P, Abedon ST. 2010. Bacteriophage host range and bacterial resistance. Adv Appl Microbiol 70:217-248. http://dx.doi.org/10.1016/S0065-2164(10)70007-1.
69. Bolger-Munro M, Cheung K, Fang A, Wang L. 2013. T4 bacteriophage average burst size varies with Escherichia coli B23 cell culture age. J Exp Microbiol Immunol 17:115-119.
70. Górski A, Międzybrodzki R, Borysowski J, Dąbrowska K, Wierzbicki P, Ohams M, Korczak-Kowalska G, Olszowska-Zaremba N, Łusiak-Szelachowska M, Kłak M, Jończyk E, Kaniuga E, Gołaś A, Purchla S, Weber-Dąbrowska B, Letkiewicz S, Fortuna W, Szufnarowski K, Pawełczyk Z, Rogóż P, Kłosowska D. 2012. Phage as a modulator of immune responses: practical implications for phage therapy. Adv Virus Res 83:41-71. http://dx.doi.org/10.1016/B978-0-12-394438-2.00002-5.
71. Międzybrodzki R, Borysowski J, Weber-Dąbrowska B, Fortuna W, Letkiewicz S, Szufnarowski K, Pawełczyk Z, Rogóż P, Kłak M, Wojtasik E, Górski A. 2012. Clinical aspects of phage therapy. Adv Virus Res 83:73-121. http://dx.doi.org/10.1016/B978-0-12-394438-2.00003-7.
72. Valyasevi R, Sandine WE, Geller BL. 1991. A membrane protein is required for bacteriophage c2 infection of Lactococcus lactis subsp. lactis C2. J Bacteriol 173:6095-6100.
73. Heeg D, Burns DA, Cartman ST, Minton NP. 2012. Spores of Clostridium difficile clinical isolates display a diverse germination response to bile salts. PLoS One 7:e32381. http://dx.doi.org/10.1371/journal.pone.0032381.
74. Whelan S, Goldman N. 2001. A general empirical model of protein evolution derived from multiple protein families using a maximum-likelihood approach. Mol Biol Evol 18:691-699. http://dx.doi.org/10.1093/oxfordjournals.molbev.a003851.
75. Hargreaves KR, Clokie J. 2015. A taxonomic review of Clostridium difficile phages and proposal of a novel genus, "Phimmp04likevirus." Viruses 7:2534-2541. http://dx.doi.org/10.3390/v7052534.
76. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. 2013. MEGA6: molecular evolutionary genetics analysis version 6.0. Mol Biol Evol 30:2725-2729. http://dx.doi.org/10.1093/molbev/mst197.